Drug therapy of advanced non-small cell lung cancer in the elderly / 中国医学科学院学报
Acta Academiae Medicinae Sinicae
;
(6): 473-476, 2010.
Article
Dans Chinois
| WPRIM
| ID: wpr-322747
ABSTRACT
About half of the elderly patients with advanced non-small cell lung cancer (NSCLC) can not receive effective treatment due to the decreased organ function and complication. Monotherapies using the third generation new drugs have became a standard first-line therapy for NSCLC, as documented by prospective phase 3 clinical trials. Combined chemotherapies that contain platin and single agent are considered optional first- and second-line treatment for patients with good physical performance and few complication. The epidermal growth factor receptor tyrosine kinase inhibitors may become a key therapeutic agent,while the role of anti-vascular endothelial growth factor monoclonal antibody remains unclear. More prospective phase 3 targeting at the elderly patients should be designed and conducted.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Carcinome pulmonaire non à petites cellules
/
Utilisations thérapeutiques
/
Traitement médicamenteux
/
Récepteurs ErbB
/
Tumeurs du poumon
/
Anticorps monoclonaux
/
Antinéoplasiques
Limites du sujet:
Adulte très âgé
/
Humains
langue:
Chinois
Texte intégral:
Acta Academiae Medicinae Sinicae
Année:
2010
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS